•Twenty-two patients received pergolide mesylate for Parkinson's disease for one year. Improvement was maximal at six months, but average functional scores were still better at 12 months than at pretreatment evaluation. On-off fluctuations were reduced in severity, and two of 18 patients experienced full resolution. Pergolide is an effective and safe ongoing medication for Parkinson's disease.
Goetz CG, Tanner CM, Glantz R, Klawans HL. Pergolide in Parkinson's Disease. Arch Neurol. 1983;40(13):785–787. doi:10.1001/archneur.1983.04050120035003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: